Blockade of adenosine A(2A) receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats

NeuroReport

Volumn 9, Issue 17, 1998, Pages 3955-3959

  Monopoli, Angela ^a   Lozza, Gianluca ^a   Forlani, Angelo ^a   Mattavelli, Amanda ^a   Ongini, Ennio ^a  

^a Faculty of Medicine   (Italy)

Author keywords

A(2A) adenosine receptor antagonist; A(2A) adenosine receptors; Focal cerebral ischaemia; Rat; SCH 58261

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2 RECEPTOR ANTAGONIST; DIZOCILPINE; NEUROPROTECTIVE AGENT; ADENOSINE RECEPTOR; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; ANIMAL; DRUG ANTAGONISM; DRUG SCREENING; SPRAGUE DAWLEY RAT; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; CEREBRAL INFARCTION; DIZOCILPINE MALEATE; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID ANTAGONISTS; ISCHEMIC ATTACK, TRANSIENT; MALE; NEUROPROTECTIVE AGENTS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1; TRIAZOLES;

EID: 0032217044     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199812010-00034     Document Type: Article

References (18)

1. Rudolphi KA, Schubert P, Parkinson FE and Fredholm BB. Trends Pharmacol Sci 13, 439-445 (1992).
2. Fredholm BB. Adenosine and neuroprotection. In: Green AR and Cross AJ, eds. Neuroprotective Agents and Cerebral Ischemia. San Diego: Academic Press, 1997: 259-280.
3. Carswell HV, Graham DI and Stone TW. J Neurochem 68, 240-247 (1997).
4. Dunwiddie TV and Fredholm BB. Adenosine neuromodulation. In: Jacobson KA and Jarvis MF, eds. Purinergic Approaches in Experimental Therapeutics. New York: Wiley-Liss, 1997: 359-382.
5. Jones PA, Smith RA, Stone TW. Neuroscience 85, 229-237 (1998).
6. Sheardown MJ and Knutsen LJS. Drug Dev Res 39, 108-114 (1996).
7. Monopoli A, Conti A, Zocchi C et al. Arzneim-Forsch (Drug Res) 44, 1296-1304 (1994).
8. Gao Y and Phillis JW. Life Sci 55, 61-65 (1994).
9. Phillis JW. Brain Res 705, 79-84 (1995).
10. Von Lubitz DKJE, Lin RCS and Jacobson KA. Eur J Pharmacol 287, 295-302 (1995).
11. Ongini E. Drug Dev Res 42, 63-70 (1997).
12. Shigeno T, McCulloch J, Graham DI et al. Surg Neurol 24, 47-51 (1985).
13. Rosen GD and Harry JD. J Neurosci Methods 35, 115-124 (1990).
14. Stone TW, Duley JA, Simmonds HA et al. Adv Exp Med Biol 431, 119-123 (1998).
15. Popoli P, Ferré S, Pezzola A et al. Eur J Pharmacol 305, 123-126 (1996).
16. Matsumoto K, Graf R, Rosner G et al. Brain Res 579, 309-314 (1992).
17. Schubert P, Ogata T, Rudolphi KA et al. Ann NY Acad Sci 826, 337-347 (1997).
18. Bona E, Aden U, Gilland G et al. Neuropharmacology 36, 1327-1338 (1997).